Abstract
While breast cancer is one of the most common cancers in women in the U.S., it is extremely rare
in men, accounting for less than 1% of all breast cancer cases. Although there are several factors
that may increase the risk of developing male breast cancer, the fundamental disease-defining
molecular pathway of this rare cancer remains unknown. As a result, male breast cancer has
been considered similar to female breast cancer even though accumulating evidence indicates
that breast cancers in men may be genetically and epigenetically distinct. Unfortunately, unlike
female breast cancer, the lack of model systems hinders the investigation of male breast cancer.
The ubiquitin/proteasome system (UPS) plays a critical role in the regulation of protein quality
control through protein degradation. Dysregulation of the UPS has been implicated in several
diseases, including neurodegenerative disorders and cancer. The UPS is composed of 3 critical
enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin
ligases (E3). While E3 ligases are often found to be dysregulated in cancer, the
pathophysiological significance of the E2 ubiquitin-conjugating enzymes remains elusive. UbcH7
(also known as Ube2l3) is one of the E2 enzymes ubiquitously expressed in various tissues and
organs. Our lab has recently discovered that UbcH7 heterozygosity (UbcH7+/) significantly
promotes the incidence of male breast cancer in MMTV-Neu mice, a mouse model of HER2+
human breast cancer. Importantly, the loss of one copy of UbcH7 does not have any effects in
female breast cancer. To the best of our knowledge, this is the first transgenic mouse model that
promotes breast cancer only in males. Based on these results, we hypothesize that UbcH7 plays
a unique role in the prevention of male breast cancer by promoting the degradation of an
oncoprotein which only influences mammary tumorigenesis in males. The ultimate goal of this
project is to identify the “male-specific oncoprotein” in breast cancer. Towards this goal, we will
first investigate the pathophysiological conditions of UbcH7+/- male mice, especially focusing on
mammary gland development (Aim 1). We will then perform in vivo 2H2O-labeling and mass
spectrometry-based proteomics to identify the substrates of UbcH7 in male mammary glands (Aim
2). Furthermore, we also plan to conduct RNA-seq to identify an altered signaling pathway(s) in
UbcH7+/- mammary glands. Despite numerous studies on breast cancer, the mechanisms that
regulate male breast cancer remain poorly understood. We expect that our studies will place
UbcH7 as a novel predisposition gene for the development of male breast cancer, serving as a
breakthrough that will open up a new direction of research in this field.